SS-31 Protocol Guide: Reconstitution, Dosing Ranges, and Cycle Length in Research

SS-31, known in clinical development as elamipretide (a mitochondria-targeted tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2), concentrates at the inner mitochondrial membrane, where it binds cardiolipin (a phospholipid unique to the inner membrane that organizes the electron-transport chain). Preclinical and mechanistic reviews describe this binding as stabilizing cardiolipin, helping preserve membrane potential and reducing oxidative stress [39940712].

When researchers ask "what is the SS-31 dose," the honest answer is that the literature documents exactly one sustained regimen in people: 40 mg once daily, subcutaneous. Stealth BioTherapeutics used this dose in the MMPOWER-2 crossover trial and again in the Phase 3 MMPOWER-3 study of primary mitochondrial myopathy [32096613][37268435]. Every reconstitution and draw-volume question below is downstream of that one figure. There is no published human dose-ranging study that establishes a validated dosing range, so "ranges" in this context means the arithmetic of preparing a solution around that reference amount, not a menu of approved doses.

Two human trials define what "40 mg/day" actually delivered and what it produced. The table summarizes the regimens as reported.

MMPOWER-2 reported a near-miss on its primary walk-distance endpoint and improvements in patient-reported fatigue that were enough to justify a pivotal trial [32096613]. MMPOWER-3, the larger and definitive study, did not meet either primary endpoint: neither the 6-minute walk test nor the fatigue score separated from placebo, though the drug was well tolerated over 24 weeks [37268435]. The dose was the same across both; the difference was scale and duration, and the larger study did not confirm the earlier signal.

Reconstitution converts the lyophilized (freeze-dried into a stable powder) peptide into a solution. The standard diluent in research handling is BAC water (bacteriostatic water, sterile water preserved with 0.9% benzyl alcohol, which permits multi-day use of a multi-dose vial). The governing relationship is simple: final concentration equals peptide mass divided by diluent volume.

For a 50 mg vial, the diluent volume you choose sets the concentration and therefore every downstream draw volume:

Units reference a U-100 insulin syringe, where 1.0 mL equals 100 units. Adding less water yields a more concentrated solution and a smaller draw volume; adding more dilutes it and raises the volume needed to hold the same mass. Standard technique for fragile peptides is to direct the diluent stream against the vial wall rather than onto the powder, then let it dissolve without shaking. For a fuller walkthrough of diluent selection and technique, see the general reconstitution reference linked in the closing section.

Once a vial is reconstituted, "how much SS-31 to inject" is pure division: draw volume equals target mass divided by the solution's concentration. The table works a 20 mg/mL solution against several reference amounts.

One practical note the arithmetic surfaces: the trial daily amount of 40 mg is a large subcutaneous volume at typical research concentrations. The clinical formulation used in MMPOWER was more concentrated than a casual reconstitution, which is why anyone modeling the trial parameter tends to reconstitute toward the higher end (25 to 50 mg/mL) to keep the injection volume in a reasonable range. None of this is an instruction to administer the compound; it is the math that maps a documented trial figure onto a prepared vial.

Handling assumptions for SS-31 follow general peptide-stability practice rather than a compound-specific published shelf-life study. Lyophilized peptide is the most stable form and is typically held frozen or refrigerated and protected from light and moisture until use. Once reconstituted with BAC water, the solution is generally refrigerated (roughly 2 to 8 C) and used within a bounded window measured in weeks, with the benzyl alcohol preservative allowing repeated withdrawals from a multi-dose vial.

Repeated freeze-thaw cycles of reconstituted solution are avoided because they degrade peptide integrity. Because published stability data specific to elamipretide in a research setting are limited, storage practice here is conservative and derived from peptide-handling norms, not from a formal SS-31 stability trial. Treat any single stated shelf life as an estimate rather than a validated figure.

There is no validated "cycle" for SS-31 in the sense the term is used informally. The published exposures were continuous daily dosing for a fixed trial duration, not on-off cycling with washout periods designed for a research protocol.

So the documented durations span roughly 4 to 24 weeks of continuous daily administration. The MMPOWER-2 crossover used a 4-week washout between arms, but that was a trial-design device to clear one condition before the next, not a recommended cycle. No study establishes an optimal cycle length, a minimum effective duration, or a rationale for intermittent dosing, because MMPOWER-3, the study long enough to test durable effect, was negative on its primary endpoints [37268435]. Questions about SS-31 clearance and dosing frequency intersect with peptide half-life, covered in the linked half-life reference.

Both MMPOWER trials delivered elamipretide subcutaneously, once daily, which is why "SS-31 subcutaneous dose" and "40 mg/day" are effectively the same question in the literature [32096613][37268435]. The Phase 3 tolerability finding is the most robust conclusion the program produced: over 24 weeks of daily subcutaneous administration, elamipretide was well tolerated, with injection-site reactions among the more commonly reported events [37268435].

That tolerability profile is a safety-and-handling observation, not an efficacy claim. It tells a research audience that the subcutaneous route sustained daily dosing for six months without the trial being stopped for safety, while separately failing to demonstrate benefit on its functional endpoints.

Honesty about the boundaries of the evidence matters more here than usual, because the pivotal trial was negative.

Explore the compound and related research references:

All products are supplied strictly for research use only (RUO) and are not for human consumption.